Prednimustine (NSC-134087, leo 1031) treatment of lymphocytic and lymphocytic-histiocytic lymphomas

Mattsson, W.; Eyben, Finn Von; Turesson, Ingemar; Wählby, Svante

doi:10.1002/1097-0142(197801)41:1<112::aid-cncr2820410117>3.0.co;2-c

Cancer

1978

DOI: 10.1002/1097-0142(197801)41:1<112::aid-cncr2820410117>3.0.co;2-c

|View full text |Cite

Prednimustine (NSC-134087, leo 1031) treatment of lymphocytic and lymphocytic-histiocytic lymphomas

W. Mattsson

Finn Von Eyben

Ingemar Turesson³

et al.

Abstract: Nineteen patients with advanced lymphocytic or lymphocytic-histiocytic lymphomas were treated with Prednimustine (NSC-134087, Leo 1031). The median induction dose was 25 mg/m2 a day by mouth (range 11-42). Ten patients had previously received radiation or chemotherapy, or both. Four patients had a complete remission and eleven a partial remission. The median duration of remission was 12.5+ months for complete responders and 5 months for partial responders. Thirteen patients had a moderate myelosuppression. One… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1979

1983

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 14 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8. 13,14) and breast cancer (11,15). Activity has also been demonstrated in a smaller number of patients with acute myelocytic leukaemia (1, 2) and ovarian carcinoma (12).…”

mentioning

confidence: 97%

Clinical Trial of Prednimustine, Leo‐1031 (NSC‐134087), in Patients with Non‐Hodgkin Lymphomata and Chronic Lymphocytic Leukaemia Previously Treated with Steroids and Alkylating Agents

Pedersen‐Bjergaard¹,

Hansen²,

Geisler³

et al. 1980

Journal of Internal Medicine

View full text Add to dashboard Cite

Prednimustine, a chlorambucil ester of prednisolone, was administered to 16 patients with non-Hodgkin lymphomata (NHL) and 14 patients with chronic lymphocytic leukaemia (CLL), all previously treated with steroids and alkylating agents. Response was obtained in 8 patients with NHL and 11 patients with CLL. Two NHL patients had long-lasting complete remissions. Median duration of response for lymphomata was 12 weeks, for CLL more than 15 weeks. Delayed reversible and rather pronounced myelosuppression was the major side-effect observed in median 6 weeks from the start of Prednimustine with a median duration of 4 weeks.

show abstract

“…8. 13,14) and breast cancer (11,15). Activity has also been demonstrated in a smaller number of patients with acute myelocytic leukaemia (1, 2) and ovarian carcinoma (12).…”

mentioning

confidence: 97%

Clinical Trial of Prednimustine, Leo‐1031 (NSC‐134087), in Patients with Non‐Hodgkin Lymphomata and Chronic Lymphocytic Leukaemia Previously Treated with Steroids and Alkylating Agents

Pedersen‐Bjergaard¹,

Hansen²,

Geisler³

et al. 1980

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

Phase II trial of prednimustine, L-1031, (NSC-134087) in advanced breast cancer

Mouridsen¹,

Kristensen²,

Nielsen³

et al. 1980

Cancer

View full text Add to dashboard Cite

The therapeutic effect of prednimustine was studied in 35 patients with advanced breast cancer resistant to previous cytotoxic and/or endocrine therapy. Response (PR + CR) was obtained in 14 patients (40%) of a median duration of five months. Among the 14 responding patients, 10 were resistant to previous endocrine therapy and chemotherapy, in all cases including alkylating agents, and 4 were resistant to previous endocrine therapy. Hematologic toxicity was rather pronounced, but other toxicities were only moderate.

show abstract

A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer

Løber¹,

Mouridsen²,

Christiansen³

et al. 1983

Cancer

View full text Add to dashboard Cite

Prednimustine is an ester of chlorambucil and prednisolone. The drug has had some activity in experimental as well as in human tumors, including breast cancer. The objective of the current study is to compare the clinical effectiveness and toxicity of prednimustine with its components of chlorambucil plus prednisolone, and to compare the clinical effectiveness and toxicity of a continuous treatment with an intermittent one. Two hundred and one patients with advanced breast cancer were randomized to the following treatments: I: prednimustine continuously; 40 mg/m2 d; II: prednimustine intermittently, 160 mg/m2 d 1 to 5, repeated every three weeks; and III: chlorambucil 8 mg/m2 d plus prednisolone 8 mg/m2 d, both given continuously. All treatments were given orally. One hundred and ninety five patients were evaluable for assessment of response to the treatments. The response rates were 21% in both of the prednimustine‐treated groups, whereas only 11% of the patients treated with chlorambucil and prednisolone responded. The duration of remission with continuous prednimustine was longer than with the other two treatment groups, but not significantly so. One hundred and ninety five patients were evaluable for assessment of hematologic toxicity. No differences were observed between the two prednimustine‐treated groups, whereas the group treated with chlorambucil plus prednisolone experienced a significantly higher degree of leukopenia and/or thrombopenia. Subjective toxicities, nausea, vomiting and psychical symptoms were only moderate in the three treatment groups, but significantly more pronounced in the group treated with intermittent prednimustine. Because of these promising results, prednimustine should be compared to other alkylating agents in patients with advanced breast cancer in randomized trials.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Prednimustine (NSC-134087, leo 1031) treatment of lymphocytic and lymphocytic-histiocytic lymphomas

Cited by 14 publications

References 7 publications

Clinical Trial of Prednimustine, Leo‐1031 (NSC‐134087), in Patients with Non‐Hodgkin Lymphomata and Chronic Lymphocytic Leukaemia Previously Treated with Steroids and Alkylating Agents

Clinical Trial of Prednimustine, Leo‐1031 (NSC‐134087), in Patients with Non‐Hodgkin Lymphomata and Chronic Lymphocytic Leukaemia Previously Treated with Steroids and Alkylating Agents

Phase II trial of prednimustine, L-1031, (NSC-134087) in advanced breast cancer

A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer

Contact Info

Product

Resources

About